Humatrix Medical key facts
- Developer of tissue engineering and regenerative medical technology designed for early-stage surgeries to treat heart diseases.
- It has raised $14.2M; the latest was Early Stage VC ($14.2M) in Dec 2025.
- Notable investors include IDG Capital, Puhua Capital, Suzhou Guofa Venture Capital, Leader Venture Capital, Shanghai Healthcare Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Humatrix Medical: the Monday email on marks, rounds and moves
Humatrix Medical funding rounds
No funding rounds for Humatrix Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Humatrix Medical investors
8 investors are on record for Humatrix Medical, including IDG Capital, Puhua Capital, Suzhou Guofa Venture Capital and Leader Venture Capital.
About Humatrix Medical
Developer of tissue engineering and regenerative medical technology designed for early-stage surgeries to treat heart diseases. The company offers development and produces allogeneic small-caliber tissue-engineered blood vessels for chronic renal failure dialysis vascular access, lower extremity arterial trauma vascular replacement, lower extremity atherosclerosis and coronary heart disease bypass surgery, thereby providing support for clinical research and innovated medical technology for cardiac medicine.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- humatrix-medical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Humatrix Medical doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.